|
|
Article: NEUROCRINE BEGINS 5TH PHASE III, GETS PATENT PROTECTION UNTIL 2020.(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- June 5, 2002
- Author:
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences Inc. kicked off its fifth Phase III trial of its insomnia product - but the first with the modified-release version - and said it was issued a patent for the chemical composition of the drug that would give the company patent exclusivity until 2020.
"It's significant," said Gary Lyons, Neurocrine's president and CEO. "We've been facing some scrutiny from others looking at our patent portfolio. People have questioned our exclusivity."
Not anymore. U.S. Patent No. 6,399,621 covers the chemical composition of indiplon for the treatment of insomnia for the next 18 years.
"This covers not only the compound, but the uses and ...